NCT01542021View on ClinicalTrials.gov

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 24, 2012

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Prostate CancerProstatic Adenocarcinoma
Interventions
DRUG

degarelix injection

Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.

DRUG

degarelix injection

Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.

DRUG

androgen deprivation therapy

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER